Generic drug spending burgeoning in U.K.; Roche teams with Ascletis in China;

@FiercePharma: Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliff. Story | Follow @FiercePharma

@EricPFierce: France's Servier under renewed scrutiny by EMA, this time for heart risks tied to Protelos, its osteoporosis drug. Article | Follow @EricPFierce

> The Pharmaceutical Research and Manufacturers of America (PhRMA) has issued a warning about the dangers of the sequestration on drug development. Item

> Swiss drugmaker Roche ($RHHBY) said it had teamed up with biotech firm Ascletis to develop and commercialize its investigative drug danoprevir in China for the treatment of the hep C virus. Article

> A study using new projection techniques forecasts that drug spending in the U.K. will grow from 3.1% to 4.1% through 2015, powered by a 10% growth in the use of generic drugs. Report

> Aeterna Zentaris has named David A. Dodd president and CEO. Report

Medical Device News

@FierceMedDev: Special Report: 2012's 10 highest-paid Med Tech CEOs. Report | Follow @FierceMedDev

@MarkHFierce: Luminex won FDA clearance of a new Dx system to help a key GI fecal test reach more patients. More | Follow @MarkHFierce

 @DamianFierce: The Life Tech saga is finally over: Thermo Fisher has inked a $13.6B deal to buy it. Release | Follow @DamianFierce

> Trial to begin in Intuitive surgical robot patient death. Story

> Boston Scientific eyes FDA approval for MRI-safe pacer. Report

> Biodesix snags $8.8M to boost lung cancer Dx commercial push. More

Biotech News

@FierceBiotech: Sanofi CEO fires surprise torpedo at Alzheimer's drug research. Report | Follow @FierceBiotech

@RyanMFierce: How much of $TMO buyout of $LIFE depends on LIFE prevailing in DNA sequencing race? Big risk. Report | Follow @RyanMFierce

> Report slams FDA's response to CRO's fraudulent study data. Article

> FDA questions benefits of GSK's respiratory contender Breo. News

> Royalty Pharma ups Elan offer in battle over shareholder support. More

> Portola rolls out $115M IPO plan as more biotech outfits go public. Story

CRO News

> Absorption Systems reaches into India with partnership. Item

> inVentiv teams with Japanese CRO to tap growing market. Report

> Catalent jumps into ADCs with Redwood deal. Story

> Indian CMO Shasun inks Alzheimer's deal with Debiopharm. Article

> Bristol-Myers picks Quintiles for central lab work. More

Biotech IT News

> Chicago's elite back global hub of biomedical data. Item

> J&J, Roche and others back tech platform to bolster translational drug research. Article

> Eric Perakslis leaves top IT job at FDA. Report

> Elsevier scoops up startup Mendeley in controversial bet on open science. Story

> Accelrys, IBM, others spotlight new tech to back pharma R&D. Article

> Study taps web software in novel clinical and genetic research of infants. More

And Finally... After leading an IT reboot at the FDA for less than two years, Eric Perakslis quietly left his position effective March 5. Story

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.